Roivant Sciences (NASDAQ:ROIV) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research report report published on Thursday, Benzinga reports. HC Wainwright currently has a $18.00 target price on the stock.

ROIV has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an overweight rating on shares of Roivant Sciences in a research note on Monday, September 9th. Piper Sandler boosted their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an overweight rating in a research report on Wednesday, July 10th. Finally, Bank of America increased their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a neutral rating in a report on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of Moderate Buy and an average price target of $17.39.

Roivant Sciences Stock Performance

Roivant Sciences stock opened at $11.97 on Thursday. The company’s 50-day moving average price is $11.46 and its 200-day moving average price is $11.06. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. The company has a market cap of $8.84 billion, a PE ratio of 2.37 and a beta of 1.25. Roivant Sciences has a twelve month low of $8.24 and a twelve month high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The company had revenue of $55.10 million during the quarter, compared to the consensus estimate of $30.72 million. During the same period last year, the company earned ($0.38) earnings per share. Roivant Sciences’s revenue was up 155.1% on a year-over-year basis. On average, equities research analysts forecast that Roivant Sciences will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently modified their holdings of the business. Rubric Capital Management LP increased its holdings in Roivant Sciences by 15.0% during the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after buying an additional 3,000,000 shares during the period. Vanguard Group Inc. boosted its position in Roivant Sciences by 14.6% during the 1st quarter. Vanguard Group Inc. now owns 8,106,332 shares of the company’s stock valued at $85,441,000 after acquiring an additional 1,030,681 shares in the last quarter. DME Capital Management LP increased its holdings in shares of Roivant Sciences by 14.8% in the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock valued at $50,852,000 after acquiring an additional 620,470 shares during the period. Norges Bank bought a new position in shares of Roivant Sciences in the 4th quarter worth $41,506,000. Finally, BlackBarn Capital Partners LP lifted its stake in shares of Roivant Sciences by 63.1% during the 2nd quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company’s stock worth $32,767,000 after purchasing an additional 1,199,406 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.